Oncology trials are complex. New technologies creating cutting-edge immunotherapy treatments are promising but add more complexity to your study. The Medelis clinical research management team is accustomed to handling most targets in oncology, including cutting-edge immunotherapy treatments and precision oncology medicine.
Medelis’ team includes world-class oncology drug development thought leaders who understand the future of personalized medicine and threshold of credibility trials. Our extensive worldwide contacts and involvement with the research community keep us close to research trends and developments.
With Medelis, you don’t get inexperienced CRAs and PM and the bait and switch tactics of some of the big CROs. We are not a training ground for people just starting in clinical research, or even oncology. All of our operational resources are highly experienced and have proven experience in oncology studies. You get a trusted team, by your side, proactively managing your study.
As we kickoff 2026, here are the operational and strategic realities shaping Q1–Q2 2026 oncology starts. Reality #1: Phase I… [read more]
Read articleAt BIO Europe 2025, we spoke with oncology sponsors across Europe and the U.S. about how they’re planning early-phase trials… [read more]
Read articleMedelis, a specialty oncology CRO focused on early-phase clinical trials, will attend BIO Europe 2025 this November in Vienna. CEO… [read more]
Read articleOncology studies can be complex. For immuno-oncology studies, there are an entirely different set of complexities that cause additional delays. Immuno-oncology is a promising area of research, with thousands of new studies launching each year. Medelis has been pioneering immunotherapy studies since 2008, running many CAR T-cell therapy studies, checkpoint inhibitor studies and bispecific antibody treatment studies.